235 related articles for article (PubMed ID: 30133120)
1. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Liu N; Hu G; Wang H; Li Z; Guo Z
J Cell Mol Med; 2018 Nov; 22(11):5300-5310. PubMed ID: 30133120
[TBL] [Abstract][Full Text] [Related]
2. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of PLK1 inhibits invasion and promotes apoptosis in glioma cells through regulating autophagy.
Wu ZY; Wei N
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2723-2733. PubMed ID: 29771424
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
Cheng MW; Wang BC; Weng ZQ; Zhu XW
Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
[TBL] [Abstract][Full Text] [Related]
6. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Koncar RF; Chu Z; Romick-Rosendale LE; Wells SI; Chan TA; Qi X; Bahassi EM
Oncotarget; 2017 Feb; 8(9):15827-15837. PubMed ID: 28178660
[TBL] [Abstract][Full Text] [Related]
7. Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Shi H; Sun S; Xu H; Zhao Z; Han Z; Jia J; Wu D; Lu J; Liu H; Yu R
Int J Nanomedicine; 2020; 15():3347-3362. PubMed ID: 32494134
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
[TBL] [Abstract][Full Text] [Related]
9. LRRC8A potentiates temozolomide sensitivity in glioma cells via activating mitochondria-dependent apoptotic pathway.
Yang C; He L; Chen G; Ning Z; Xia Z
Hum Cell; 2019 Jan; 32(1):41-50. PubMed ID: 30426452
[TBL] [Abstract][Full Text] [Related]
10. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
11. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.
Ulasov IV; Nandi S; Dey M; Sonabend AM; Lesniak MS
Mol Med; 2011; 17(1-2):103-12. PubMed ID: 20957337
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
15. Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Min X; Dingchao X; Xun Z; Cunzu W
Turk Neurosurg; 2022; 32(3):357-363. PubMed ID: 35615767
[TBL] [Abstract][Full Text] [Related]
16. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y
J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582
[TBL] [Abstract][Full Text] [Related]
17. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
[TBL] [Abstract][Full Text] [Related]
18. Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Xu X; Wang Z; Liu N; Cheng Y; Jin W; Zhang P; Wang X; Yang H; Liu H; Zhang Y; Tu Y
Int J Oncol; 2018 Jul; 53(1):189-202. PubMed ID: 29749469
[TBL] [Abstract][Full Text] [Related]
19. Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
Chio CC; Chen KY; Chang CK; Chuang JY; Liu CC; Liu SH; Chen RM
BMC Cancer; 2018 Apr; 18(1):379. PubMed ID: 29614990
[TBL] [Abstract][Full Text] [Related]
20. EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Zhang Y; Wang SX; Ma JW; Li HY; Ye JC; Xie SM; Du B; Zhong XY
J Neurooncol; 2015 Jan; 121(1):41-52. PubMed ID: 25173233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
